American Century Companies
ABUS icon

American Century Companies’s Arbutus Biopharma ABUS Stock Holding History

American Century Companies’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,660
Closed -$41K – 2884
2024
Q3 		$41K Sell
10,660
-7,826
-42% -$30K ﹤0.01% 2870
2024
Q2 		$57.1K Sell
18,486
-107,728
-85% -$323K ﹤0.01% 2855
2024
Q1 		$326K Buy
126,214
+43,814
+53% +$113K ﹤0.01% 2612
2023
Q4 		$206K Buy
82,400
+64,627
+364% +$127K ﹤0.01% 2682
2023
Q3 		$36.1K Buy
17,773
+7,113
+67% +$14.9K ﹤0.01% 2822
2023
Q2 		$24.5K Buy
+10,660
New +$27.7K ﹤0.01% 2781
2018
Q3 		– Sell
-11,121
Closed -$81K – 1252
2018
Q2 		$81K Buy
+11,121
New +$66.2K ﹤0.01% 1278

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

American Century Companies's ABUS Position: Q4 2024 in Review

American Century Companies sold out of Arbutus Biopharma (ABUS) in Q4 2024, closing a stake of 10,660 shares — an estimated $41K sold.

American Century Companies first reported a position in ABUS in Q2 2018 and held it in 7 quarters. The position peaked at $326K in Q1 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • American Century Companies reported no remaining Arbutus Biopharma position as of Q4 2024 after selling out during the quarter.
  • American Century Companies sold 10,660 Arbutus Biopharma shares in Q4 2024, an estimated $41K.
  • American Century Companies first reported a position in Arbutus Biopharma in Q2 2018 and held it in 7 quarters.
  • American Century Companies's Arbutus Biopharma position peaked at $326K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on American Century Companies's 13F filing for Q4 2024, filed 11 Feb 2025.